111 patents
Page 6 of 6
Utility
Treating Seizure with Recombinant Alkaline Phosphatase
25 Mar 20
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Andre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
Filed: 17 Oct 19
Utility
Compositions and Methods for the Treatment of Neuromyelitis Optica
25 Mar 20
Provided are methods of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Fanny O'Brien
Filed: 19 Sep 19
Utility
Methods and Compositions for Treating Complement-associated Disorders
4 Mar 20
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders.
Russell P. Rother
Filed: 19 Mar 19
Utility
Lysosomal Storage Disease Enzymes
26 Feb 20
The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Anthony Quinn, Alex J. Harvey
Filed: 8 Jul 19
Utility
Assay for C5B-9 Deposition In Complement-associated Disorders
19 Feb 20
Provided herein are methods of detecting C5b-9 deposition on endothelial cells.
Miriam GALBUSERA, Marina NORIS, Giuseppe REMUZZI
Filed: 25 Oct 17
Utility
Methods for Reducing Liver Fibrosis and Treating Lysosomal Acid Lipase Deficiency In Patients Based on Ishak Fibrosis Stage
5 Feb 20
The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.
Anthony QUINN, Zachary GOODMAN, Barbara BURTON, Andrew RANKIN, Mark FRIEDMAN, Paresh SONI
Filed: 27 Sep 17
Utility
Method for Simultaneous Quantification of ALXN1210 and Eculizumab In Human Serum or Urine
29 Jan 20
Provided herein are methods for simultaneously detecting and quantifying antibodies which bind to the same target and have high sequence identity, such as eculizumab and ALXN1210, present together or alone in a biological sample.
Meng CHEN, Ryan PELTO
Filed: 27 Mar 18
Utility
Compositions and Methods for Increasing the Serum Half-life of a Therapeutic Agent Targeting Complement C5
22 Jan 20
The disclosure features compositions and methods for increasing the half-life of a therapeutic agent (e.g., a C5 antagonist) in the serum of a subject (e.g. a human).
Jeffrey William Hunter, Paul P. Tamburini
Filed: 28 May 19
Utility
Monovalent Anti-properdin Antibodies and Antibody Fragments
20 Nov 19
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin.
Douglas L. SHERIDAN, Paul P. TAMBURINI, Taneisha Ann-Tanara MACK, Walter C. VOEGTLI
Filed: 29 Jan 18
Utility
Prolongation of Survival of an Allograft by Inhibiting Complement Activity
9 Oct 19
Methods of prolonging survival of allotransplanted cells, tissues or organs are presented.
Russell P. ROTHER, Hao WANG, Zhen ZHONG - DECEASED
Filed: 13 Nov 18
Utility
Identifying Effective Dosage Regimens for Tissue Non-specific Alkaline Phosphatase (Tnsalp)-enzyme Replacement Therapy of Hypophosphatasia
2 Oct 19
A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
Rajendra PRADHAN, Xiang GAO
Filed: 26 Sep 16